Sandoz CEO Richard Saynor has reportedly stated that the proposal to introduce a Europe-wide list price for new medicines is ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide ...

mid single-digit net-sales growth[1] and core EBITDA margin of around 21% Richard Saynor, Chief Executive Officer of Sandoz, commented: “With Q1 sales in line with our expectations, we have now ...

often life-saving medicines is something we simply cannot take for granted,” says Richard Saynor, CEO of generic medicines company Sandoz. A resilient supply chain is one that not only delivers ...

Richard Saynor told Reuters that the proposal - outlined in a letter to the Financial Times last week - ignores structural drivers of high drug prices in the United States. "It made me smile ...